Pharmacokinetics of the new beta-adrenoceptor blocker SL 75212 in man after repeated oral administration [proceedings]. - Suppr | 超能文献

Pharmacokinetics of the new beta-adrenoceptor blocker SL 75212 in man after repeated oral administration [proceedings].

作者信息

Bianchetti G, Blatrix C, Gomeni R, Kilborn J R, Larribaud J, Lücker P W, Morselli P L, Thébault J J, Trocherie S

出版信息

Br J Clin Pharmacol. 1979 Oct;8(4):408P. doi: 10.1111/j.1365-2125.1979.tb04755.x.

DOI:10.1111/j.1365-2125.1979.tb04755.x

PMID:41560

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pharmacokinetics of the new beta-adrenoceptor blocker SL 75212 in man after repeated oral administration [proceedings].

Br J Clin Pharmacol. 1979 Oct;8(4):408P. doi: 10.1111/j.1365-2125.1979.tb04755.x.

2

Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.新型β-肾上腺素能受体阻滞剂倍他洛尔（SL 75212）多次口服给药后在人体的药代动力学

Arzneimittelforschung. 1980;30(11):1912-6.

3

Comparison of the beta-adrenoceptor blocking properties and pharmacokinetics of SL 75212 and propranolol in man [proceedings].SL 75212与普萘洛尔在人体中的β-肾上腺素能受体阻断特性及药代动力学比较[会议论文集]

Br J Clin Pharmacol. 1979 Oct;8(4):407P-708P. doi: 10.1111/j.1365-2125.1979.tb04754.x.

4

[The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].[1-(4-环己基脲基苯氧基)-2-羟基-3-叔丁氨基丙烷（他林洛尔，Cordanum，02-115）的药代动力学 2. 大鼠体内14C标记化合物的排泄、血药浓度及分布]

Pharmazie. 1975 Oct;30(10):675-7.

5

Pharmacokinetics of betaxolol in middle aged patients.倍他洛尔在中年患者中的药代动力学

Eur J Clin Pharmacol. 1986;31(2):231-3. doi: 10.1007/BF00606665.

6

Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man.布托非诺洛尔（卡菲德）在人体重复口服给药后的药代动力学。

Int J Clin Pharmacol Res. 1984;4(3):175-83.

7

Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects.

World Rev Nutr Diet. 1984;43:183-6. doi: 10.1159/000409071.

8

Pharmacokinetics of flestolol in man: preliminary data.氟司洛尔在人体中的药代动力学：初步数据。

Br J Clin Pharmacol. 1985 Dec;20(6):691-4. doi: 10.1111/j.1365-2125.1985.tb05131.x.

9

Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.β受体拮抗剂纳多洛尔的药代动力学：对高血压患者给予治疗性单剂量和多剂量方案

J Clin Pharmacol. 1979 Nov-Dec;19(11-12):712-20. doi: 10.1002/j.1552-4604.1979.tb01641.x.

10

Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].新型β-肾上腺素能受体拮抗剂SL 75212口服和静脉给药后的血药浓度及药效学效应[会议论文]

Br J Clin Pharmacol. 1979 Oct;8(4):403P-404P.

引用本文的文献

1

Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoceptor antagonists in man.在评估人β-肾上腺素能拮抗剂选择性过程中环境温度和湿度对支气管反应的影响

Br J Clin Pharmacol. 1981 Aug;12(2):201-9. doi: 10.1111/j.1365-2125.1981.tb01201.x.

2

Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.倍他洛尔。对其药效学、药代动力学特性及在高血压治疗中的疗效的综述。

Drugs. 1986 Jan;31(1):6-28. doi: 10.2165/00003495-198631010-00002.